European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
Authors
KROESE, Tiuri E, Sebastiaan BRONZWAER, Peter S N VAN ROSSUM, Sebastian F SCHOPPMAN, Pieter R A J DESEYNE, Eric VAN CUTSEM, Karin HAUSTERMANS, Philippe NAFTEUX, Melissa THOMAS, Radka LORDICK OBERMANNOVÁ (203 Czech Republic, belonging to the institution), Hanna R MORTENSEN, Marianne NORDSMARK, Per PFEIFFER, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Christiane J BRUNS, Florian LORDICK, Ines GOCKEL, Markus MOEHLER, Cihan GANI, Theodore LIAKAKOS, John V REYNOLDS, Alessio G MORGANTI, Riccardo ROSATI, Carlo CASTORO, Francesco CELLINI, Domenico D'UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Mark I van Berge HENEGOUWEN, Maarten C C M HULSHOFF, Jolanda VAN DIEREN, Marieke VOLLEBERGH, Johanna W VAN SANDICK, Paul JEENE, Christel MUIJS, Marije SLINGERLAND, Francine E M VONCKEN, Henk HARTGRINK, Geert-Jan CREEMERS, Maurice J C VAN DER SANGEN, Grard A P NIEUWENHUIJZEN, Maaike BERBEE, Marcel VERHEIJ, Bas WIJNHOVEN, V Beerepoot LAURENS, Nadia Haj MOHAMMAD, Stella MOOK, Jelle P RUURDA, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Lucjan WYRWICZ, Maria ALSINA, Josep TABERNERO, Manuel PERA, Tania F KANONNIKOFF, Andres CERVANTES, Magnus NILSSON, Stefan MONIG, Anna D WAGNER, Matthias GUCKENBERGER, Ewen A GRIFFITHS, Elizabeth SMYTH, George B HANNA, Sheraz MARKAR, M Asif CHAUDRY, Maria A HAWKINS, Edward CHEONG, Hanneke W M VAN LAARHOVEN and Richard VAN HILLEGERSBERG
Edition
European Journal of Cancer, London, ELSEVIER, 2024, 0959-8049
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Introduction: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Methods: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. Results: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with <= 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. F-18-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI <= 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. Discussion: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.
KROESE, Tiuri E, Sebastiaan BRONZWAER, Peter S N VAN ROSSUM, Sebastian F SCHOPPMAN, Pieter R A J DESEYNE, Eric VAN CUTSEM, Karin HAUSTERMANS, Philippe NAFTEUX, Melissa THOMAS, Radka LORDICK OBERMANNOVÁ, Hanna R MORTENSEN, Marianne NORDSMARK, Per PFEIFFER, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Christiane J BRUNS, Florian LORDICK, Ines GOCKEL, Markus MOEHLER, Cihan GANI, Theodore LIAKAKOS, John V REYNOLDS, Alessio G MORGANTI, Riccardo ROSATI, Carlo CASTORO, Francesco CELLINI, Domenico D'UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Mark I van Berge HENEGOUWEN, Maarten C C M HULSHOFF, Jolanda VAN DIEREN, Marieke VOLLEBERGH, Johanna W VAN SANDICK, Paul JEENE, Christel MUIJS, Marije SLINGERLAND, Francine E M VONCKEN, Henk HARTGRINK, Geert-Jan CREEMERS, Maurice J C VAN DER SANGEN, Grard A P NIEUWENHUIJZEN, Maaike BERBEE, Marcel VERHEIJ, Bas WIJNHOVEN, V Beerepoot LAURENS, Nadia Haj MOHAMMAD, Stella MOOK, Jelle P RUURDA, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Lucjan WYRWICZ, Maria ALSINA, Josep TABERNERO, Manuel PERA, Tania F KANONNIKOFF, Andres CERVANTES, Magnus NILSSON, Stefan MONIG, Anna D WAGNER, Matthias GUCKENBERGER, Ewen A GRIFFITHS, Elizabeth SMYTH, George B HANNA, Sheraz MARKAR, M Asif CHAUDRY, Maria A HAWKINS, Edward CHEONG, Hanneke W M VAN LAARHOVEN and Richard VAN HILLEGERSBERG. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). European Journal of Cancer. London: ELSEVIER, 2024, vol. 204, June 2024, p. 1-9. ISSN 0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2024.114062.
@article{2423181, author = {Kroese, Tiuri E and Bronzwaer, Sebastiaan and van Rossum, Peter S N and Schoppman, Sebastian F and Deseyne, Pieter R A J and van Cutsem, Eric and Haustermans, Karin and Nafteux, Philippe and Thomas, Melissa and Lordick Obermannová, Radka and Mortensen, Hanna R and Nordsmark, Marianne and Pfeiffer, Per and Elme, Anneli and Adenis, Antoine and Piessen, Guillaume and Bruns, Christiane J and Lordick, Florian and Gockel, Ines and Moehler, Markus and Gani, Cihan and Liakakos, Theodore and Reynolds, John V and Morganti, Alessio G and Rosati, Riccardo and Castoro, Carlo and Cellini, Francesco and D'Ugo, Domenico and Roviello, Franco and Bencivenga, Maria and Giovanni, de Manzoni and Henegouwen, Mark I van Berge and Hulshoff, Maarten C C M and van Dieren, Jolanda and Vollebergh, Marieke and van Sandick, Johanna W and Jeene, Paul and Muijs, Christel and Slingerland, Marije and Voncken, Francine E M and Hartgrink, Henk and Creemers, GeertandJan and van der Sangen, Maurice J C and Nieuwenhuijzen, Grard A P and Berbee, Maaike and Verheij, Marcel and Wijnhoven, Bas and Laurens, V Beerepoot and Mohammad, Nadia Haj and Mook, Stella and Ruurda, Jelle P and Kolodziejczyk, Piotr and Polkowski, Wojciech P and Wyrwicz, Lucjan and Alsina, Maria and Tabernero, Josep and Pera, Manuel and Kanonnikoff, Tania F and Cervantes, Andres and Nilsson, Magnus and Monig, Stefan and Wagner, Anna D and Guckenberger, Matthias and Griffiths, Ewen A and Smyth, Elizabeth and Hanna, George B and Markar, Sheraz and Chaudry, M Asif and Hawkins, Maria A and Cheong, Edward and van Laarhoven, Hanneke W M and van Hillegersberg, Richard}, article_location = {London}, article_number = {June 2024}, doi = {http://dx.doi.org/10.1016/j.ejca.2024.114062}, keywords = {Esophageal cancer; Gastric cancer; Metastasis; Metastasectomy; Stereotactic body radiotherapy; Oligometastasis}, language = {eng}, issn = {0959-8049}, journal = {European Journal of Cancer}, title = {European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)}, url = {https://www.sciencedirect.com/science/article/pii/S0959804924007184?via%3Dihub}, volume = {204}, year = {2024} }
TY - JOUR ID - 2423181 AU - Kroese, Tiuri E - Bronzwaer, Sebastiaan - van Rossum, Peter S N - Schoppman, Sebastian F - Deseyne, Pieter R A J - van Cutsem, Eric - Haustermans, Karin - Nafteux, Philippe - Thomas, Melissa - Lordick Obermannová, Radka - Mortensen, Hanna R - Nordsmark, Marianne - Pfeiffer, Per - Elme, Anneli - Adenis, Antoine - Piessen, Guillaume - Bruns, Christiane J - Lordick, Florian - Gockel, Ines - Moehler, Markus - Gani, Cihan - Liakakos, Theodore - Reynolds, John V - Morganti, Alessio G - Rosati, Riccardo - Castoro, Carlo - Cellini, Francesco - D'Ugo, Domenico - Roviello, Franco - Bencivenga, Maria - Giovanni, de Manzoni - Henegouwen, Mark I van Berge - Hulshoff, Maarten C C M - van Dieren, Jolanda - Vollebergh, Marieke - van Sandick, Johanna W - Jeene, Paul - Muijs, Christel - Slingerland, Marije - Voncken, Francine E M - Hartgrink, Henk - Creemers, Geert-Jan - van der Sangen, Maurice J C - Nieuwenhuijzen, Grard A P - Berbee, Maaike - Verheij, Marcel - Wijnhoven, Bas - Laurens, V Beerepoot - Mohammad, Nadia Haj - Mook, Stella - Ruurda, Jelle P - Kolodziejczyk, Piotr - Polkowski, Wojciech P - Wyrwicz, Lucjan - Alsina, Maria - Tabernero, Josep - Pera, Manuel - Kanonnikoff, Tania F - Cervantes, Andres - Nilsson, Magnus - Monig, Stefan - Wagner, Anna D - Guckenberger, Matthias - Griffiths, Ewen A - Smyth, Elizabeth - Hanna, George B - Markar, Sheraz - Chaudry, M Asif - Hawkins, Maria A - Cheong, Edward - van Laarhoven, Hanneke W M - van Hillegersberg, Richard PY - 2024 TI - European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4) JF - European Journal of Cancer VL - 204 IS - June 2024 SP - 1-9 EP - 1-9 PB - ELSEVIER SN - 09598049 KW - Esophageal cancer KW - Gastric cancer KW - Metastasis KW - Metastasectomy KW - Stereotactic body radiotherapy KW - Oligometastasis UR - https://www.sciencedirect.com/science/article/pii/S0959804924007184?via%3Dihub N2 - Introduction: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Methods: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. Results: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with <= 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. F-18-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI <= 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. Discussion: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment. ER -
KROESE, Tiuri E, Sebastiaan BRONZWAER, Peter S N VAN ROSSUM, Sebastian F SCHOPPMAN, Pieter R A J DESEYNE, Eric VAN CUTSEM, Karin HAUSTERMANS, Philippe NAFTEUX, Melissa THOMAS, Radka LORDICK OBERMANNOVÁ, Hanna R MORTENSEN, Marianne NORDSMARK, Per PFEIFFER, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Christiane J BRUNS, Florian LORDICK, Ines GOCKEL, Markus MOEHLER, Cihan GANI, Theodore LIAKAKOS, John V REYNOLDS, Alessio G MORGANTI, Riccardo ROSATI, Carlo CASTORO, Francesco CELLINI, Domenico D'UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Mark I van Berge HENEGOUWEN, Maarten C C M HULSHOFF, Jolanda VAN DIEREN, Marieke VOLLEBERGH, Johanna W VAN SANDICK, Paul JEENE, Christel MUIJS, Marije SLINGERLAND, Francine E M VONCKEN, Henk HARTGRINK, Geert-Jan CREEMERS, Maurice J C VAN DER SANGEN, Grard A P NIEUWENHUIJZEN, Maaike BERBEE, Marcel VERHEIJ, Bas WIJNHOVEN, V Beerepoot LAURENS, Nadia Haj MOHAMMAD, Stella MOOK, Jelle P RUURDA, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Lucjan WYRWICZ, Maria ALSINA, Josep TABERNERO, Manuel PERA, Tania F KANONNIKOFF, Andres CERVANTES, Magnus NILSSON, Stefan MONIG, Anna D WAGNER, Matthias GUCKENBERGER, Ewen A GRIFFITHS, Elizabeth SMYTH, George B HANNA, Sheraz MARKAR, M Asif CHAUDRY, Maria A HAWKINS, Edward CHEONG, Hanneke W M VAN LAARHOVEN and Richard VAN HILLEGERSBERG. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). \textit{European Journal of Cancer}. London: ELSEVIER, 2024, vol.~204, June 2024, p.~1-9. ISSN~0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2024.114062.